Vlak T, Jajić I
Bolnica za reumatske bolesti i rehabilitaciju, Split.
Reumatizam. 1992;39(2):1-5.
The objective of this research has been to determine the efficacy of Na-aurothiomalate, under the trade name Tauredon, on the development of circulating immune complexes (CIC) in patients with rheumatoid arthritis. During a continuous six month administering of Tauredon to a group of patients with the diagnosis of rheumatoid arthritis various parameters have been observed. The group comprised 43 patients, 8 men and 35 women, their average age being 50. By continuous observations of both the patients and their laboratory reports in regular intervals during six-month administering of Tauredon, a positive effect of Tauredon on the development of the CIC IgM values (P = 0.006) has been proved, i.e. reducing their level in the patients' serum. Owing to great individual differences in the decrease of the CIC IgG values, it has been difficult to prove the consequences of this fall (P = 0.086). The impossibility of testing the significant decrease of the CIC IgA values is due to a small number of patients with the positive CIC IgA values.
本研究的目的是确定商品名为Tauredon的金硫葡糖对类风湿性关节炎患者循环免疫复合物（CIC）形成的疗效。在对一组诊断为类风湿性关节炎的患者连续六个月使用Tauredon的过程中，观察了各项参数。该组包括43名患者，8名男性和35名女性，平均年龄为50岁。通过在六个月使用Tauredon期间定期对患者及其实验室报告进行连续观察，已证明Tauredon对CIC IgM值的形成有积极作用（P = 0.006），即降低了患者血清中的水平。由于CIC IgG值下降存在很大的个体差异，难以证明这种下降的后果（P = 0.086）。无法检测到CIC IgA值显著下降是由于CIC IgA值呈阳性的患者数量较少。
